The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.

@article{Sesti2004TheAV,
  title={The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.},
  author={Giorgio Sesti and Maria Alelaide Marini and Marina Cardellini and Angela Sciacqua and Simona Frontoni and Francesco Andreozzi and Concetta Irace and Davide Lauro and Agostino Gnasso and Massimo Federici and Francesco Perticone and Renato Lauro},
  journal={Diabetes care},
  year={2004},
  volume={27 6},
  pages={
          1394-8
        }
}
OBJECTIVE The aim of this study was to investigate whether diabetic patients carrying the Arg(972) insulin receptor substrate-1 (IRS-1) variant are at increased risk for secondary failure to sulfonylurea. RESEARCH DESIGN AND METHODS A total of 477 unrelated Caucasian type 2 diabetic patients were recruited according to the following criteria: onset of diabetes after age 35 years, absence of ketonuria at diagnosis, and anti-GAD(-) antibody. Type 2 diabetes was diagnosed according to the… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 25 CITATIONS

Similar Papers

Loading similar papers…